Botanix Pharmaceuticals (ASX:BOT) received firm commitments to raise AU$40 million via a non-underwritten institutional placement, according to a Tuesday filing with the Australian bourse.
The placement is for the issue of roughly 121.2 million new fully paid ordinary shares at AU$0.33 apiece. The price is a 7% discount to the company's last traded price before the trading halt on April 14, per the filing.
Proceeds will be used to fund the commercialization of Sofdra in the US. Sofdra aims to treat primary axillary hyperhidrosis.
Botanix Pharmaceuticals' shares were up past 10% in recent Tuesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。